Piper Sandler Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Biren Amin maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) but lowers the price target from $205 to $200.
August 08, 2024 | 11:27 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler analyst Biren Amin maintains an Overweight rating on Sarepta Therapeutics but lowers the price target from $205 to $200.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. The net impact is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100